Genetic Analyses of Early-Onset Alzheimer’s Disease Using Next Generation Sequencing

Genetic analyses of early-onset Alzheimer’s disease using next generation sequencing

Alzheimer’s disease (AD) is the most common type of neurodegenerative dementia, but the cause of AD remained poorly understood. Many mutations in the amyloid precursor protein (APP) and presenilin 1 and 2 (PSEN1 and PSEN2) have been reported as the pathogenic causes of early-onset AD (EOAD), which accounts for up to 5% of all AD cases. In this study, we screened familiar/de novo EOAD (n = 67) samples by next-generation sequencing (NGS) of a 50-g…

First large-scale stem cell bank enables worldwide studies on genetic risk for Alzheimer's disease

Alzheimer's disease (AD) is a common, debilitating neurodegenerative disease affecting about 10% of people over the age of 65 and one third of people aged 85 and above. Besides environmental factors, the genes have a strong influence on whether or not a person develops AD during their lifetime.

Cognito Achieves Enrolment Target In Trial Of Spectris System For AD - Data Intelligence

The primary aim of the study is to evaluate Spectris’ efficacy in slowing the progression of Alzheimer’s against sham for mild to moderate patients. Credit: PeopleImages.com – Yuri A / Shutterstock. Cognito Therapeutics has reached its enrolment goal for the randomised, sham-controlled HOPE Study investigating the Spectris AD system’s efficacy and safety in treating Alzheimer’s disease. The double-blind trial, with 670 subjects enrolled, is set …

Early-Onset Alzheimer’s disease and amyloid precursor protein gene mutations

Early-onset Alzheimer’s disease (EOAD) is a form of Alzheimer’s disease (AD) that usually manifests before the age of 65 years and is closely l